SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Sionic AI, a South Korean startup led by CEO Seok-Hyun Koh, has recently signed a Memorandum of Understanding (MOU) with Alibaba Cloud, the digital technology and innovation backbone of Alibaba Group. By joining forces, this partnership aims to create synergies between Generative AI and Cloud technologies, enhancing Sionic AI's competitiveness in the global market through technology and networking support from Alibaba Cloud.
To explore partnering with Sionic AI, please reach out to: contact@sionic.ai
For tailored AI solutions, Sionic AI's 'STORM Platform' enables enterprise clients to design, operate, and enhance customized generative AI, particularly large language models (LLMs). The company recently has built significant momentum and interest, having secured 4 million USD in funding from investors such as Korea Investment Partners, IMM Investment, Samsung Venture Investment, and Hillspring Investment. Sionic AI is also expanding its B2B operations through various collaborations with large Korean enterprises.
Seok-Hyun Koh, CEO of Sionic AI, commented: "The collaboration with Alibaba Cloud is a significant opportunity for us. We plan to bring our innovative AI solutions to more customers and expect rapid expansion beyond the domestic market — to Japan, China, and Southeast Asia — playing a key role in Alibaba Cloud's global business strategy."
Leveraging Alibaba Cloud's highly scalable, robust and secure infrastructure, Sionic AI plans to expand its service offerings to cloud-based generative AI services (SaaS) and tailored infrastructure solutions for enterprises, encompassing Managed Service Provider (MSP) operations.
For more information: https://sionic.ai
Contact: contact@sionic.ai
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Sionic AI Partners with Alibaba Cloud for Global Collaboration
BARCELONA, Spain, Sept. 17, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.
Pioneering Advances in mRNA Therapeutics
WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and the US, demonstrated exceptional safety, immunogenicity, and anti-tumor activity in the latest clinical trials. The vaccine is being developed specifically for adult patients with advanced EBV-positive solid tumours and refractory or relapsed EBV-positive lymphomas, diseases for which there are currently no effective, low-toxicity treatment options.
Impressive Clinical Performance Recognized by ESMO
Interim clinical data presented at ESMO 2024 highlighted the vaccine's ability to activate the patient's immune system, leading to the production of cytotoxic T cells, antigen-specific antibodies and memory T cells that target and destroy cancer cells. This novel mechanism offers a promising alternative to conventional CAR-T and monoclonal antibody therapies and also aims to prevent tumor recurrence, providing a triple benefit, particularly for patients with late-stage nasopharyngeal carcinoma and NK/T cell lymphoma.
Innovative Technology and Global Impact
WGc-043 is a testament to WestGene's proprietary mRNA platform, which includes cutting-edge innovations in mRNA sequence design, novel lipid nanoparticle (LNP) delivery systems, and scalable manufacturing processes. The vaccine was developed using WestGene's patented LNP technology, which is recognized for its superior efficacy and safety. This technology has been instrumental in overcoming the challenges associated with mRNA vaccine delivery and has positioned WestGene as a leader in the global mRNA therapeutic
Expanding Horizons in Cancer Treatment
The global market for mRNA cancer vaccines is expected to grow significantly, with estimates ranging from $230 billion to $300 billion by 2035. The success of WGc-043 at ESMO underscores the potential of mRNA technology not only to lead the field, but also to accelerate clinical development and provide safe, effective treatments for late-stage cancer patients.
Looking Ahead
WestGene Biopharma (www.westgenepharma.com) remains committed to advancing its mRNA platform and expanding its pipeline to address unmet medical needs across a range of indications. The company's innovative approach and commitment to collaboration will continue to drive progress in the field of mRNA therapeutics and bring hope to patients worldwide.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
